An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021)
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.
Abstract
Purpose Genexol-PM is a biodegradable cremophor EL–free polymeric micelle formulation of paclitaxel. Here, we compared efficacy and safety of Genexol-PM plus carboplatin versus Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods In this multicenter, randomized, phase II study, patients with International Federation of Gynecology and Obstetrics IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 area under the curve carboplatin every 3 weeks (6 cycles). The primary endpoint was the carbohydrate antigen 125 and Response Evaluation Criteria In Solid Tumor composite overall response rate (ORR). Results Of 131 enrolled patients, 98 were included in intention-to-treat analysis. Mean dosages were 260.00±0.00 mg/m2 Genexol-PM or 174.24±3.81 mg/m2 Genexol. Median followup was 18.0 months (range, 6.1 to 33.8 months). ORR was 88.0% (95% confidence interval [CI], 80.4 to 95.6) with Genexol-PM, and 77.1% (95% CI, 67.1 to 87.1) with Genexol (noninferiority threshold, 16.3%). Median time to progression was 14.8 months (95% CI, 11.3 to 20.2) with Genexol-PM and 15.4 months (95% CI, 13.2 to 29.6) with Genexol (p=0.550). Overall, six patients died. Neutropenia was the most common toxicity (incidences of 86.0% vs. 77.1%, p=0.120). Peripheral neuropathy incidences were 84.0% versus 64.6% (p= 0.148). Peripheral neuropathy of ! grade 3 occurred in one patient receiving Genexol. All toxicities were manageable. Conclusion Genexol-PM plus carboplatin as first-line treatment in patients with epithelial ovarian cancer demonstrated non-inferior efficacy and well-tolerated toxicities compared with the standard paclitaxel regimen. Further studies are warranted to optimize the dose and schedule, and to investigate long-term outcomes.
참고문헌 (29)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)[DOI]
- Annual report of cancer statistics in Korea in 2012, "Korea Central Cancer Registry", National Cancer Center, ~ (2014)
- Ozols RF, "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study", J Clin Oncol, 21, pp.3194~3200 (2003)[DOI]
- Burger RA, "Incorporation of bevacizumab in the primary treatment of ovarian cancer", N Engl J Med, 365, pp.2473~2483 (2011)[DOI]
- Katsumata N, "Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial", Lancet Oncol, 14, pp.1020~1026 (2013)[DOI]
- Chan JK, "Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer", N Engl J Med, 374, pp.738~748 (2016)[DOI]
- Gelderblom H, "Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation", Eur J Cancer, 37, pp.1590~1598 (2001)[DOI]
- Kintzel PE, "Prophylaxis for paclitaxel hypersensitivity reactions", Ann Pharmacother, 35, pp.1114~1117 (2001)[DOI]
- Kloover JS, "Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens", Br J Cancer, 90, pp.304~305 (2004)[DOI]
- Kim SC, "In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy", J Control Release, 72, pp.191~202 (2001)[DOI]
- Kim TY, "Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies", Clin Cancer Res, 10, pp.3708~3716 (2004)[DOI]
- "Abstracts of the 43rd Annual Meeting of the Society of Gynecologic Oncology. March 24-27, 2012. Austin, Texas, USA", Gynecol Oncol., 125(Suppl 1), pp.S2~S188 (2012)[DOI]
- Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, 92, pp.205~216 (2000)[DOI]
- Rustin GJ, "Use of CA-125 to assess response to new agents in ovarian cancer trials", J Clin Oncol, 21(10 Suppl), pp.187s~193s (2003)[DOI]
- Crown J, "The taxanes: an update", Lancet, 355, pp.1176~1178 (2000)[DOI]
- Rowinsky EK, "Paclitaxel (taxol)", N Engl J Med, 332, pp.1004~1014 (1995)[DOI]
- Sparreboom A, "Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications", Cancer Res, 59, pp.1454~1457 (1999)
- van Zuylen L, "Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles", Cancer Chemother Pharmacol, 47, pp.309~318 (2001)[DOI]
- Lee KS, "Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer", Breast Cancer Res Treat, 108, pp.241~250 (2008)[DOI]
- Kim DW, "Multicenter phase II trial of Genexol-PM, a novel Cremophorfree, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer", Ann Oncol, 18, pp.2009~2014 (2007)[DOI]
- Lee JL, "Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum", Invest New Drugs, 30, pp.1984~1990 (2012)[DOI]
- Saif MW, "Phase II clinical trial of paclitaxel loaded polymeric micelle in patients with advanced pancreatic cancer", Cancer Invest, 28, pp.186~194 (2010)
- Winer EP, "Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342", J Clin Oncol, 22, pp.2061~2068 (2004)[DOI]
- Gradishar WJ, "Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer", J Clin Oncol, 23, pp.7794~7803 (2005)[DOI]
- Socinski MA, "Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial", J Clin Oncol, 30, pp.2055~2062 (2012)[DOI]
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)[DOI]
- Rugo HS, "Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound Nabpaclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502", NCCTG N063H (Alliance), 2015, pp.33, 2361~2369
- Untch M, "Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial", Lancet Oncol, 17, pp.345~356 (2016)[DOI]
- Scripture CD, "Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives", Curr Neuropharmacol, 4, pp.165~172 (2006)[DOI]